Fig. 4: Chemical derivatization and bioactivity profiling of jawsamycin. | Nature Communications

Fig. 4: Chemical derivatization and bioactivity profiling of jawsamycin.

From: Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol

Fig. 4

Chemical variation of the dihydro uracil moiety (a-series) the dihydro uridine moiety (b-series) and the cyclopropylated fatty acid tail moiety (c-series) was undertaken with the natural compound as starting material. The obtained jawsamycin derivatives (numbered JD-X) were purified, structure verified and tested against the indicated four different fungal pathogens to obtain minimal effective concentrations (MEC).

Back to article page